162 related articles for article (PubMed ID: 6825083)
21. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells.
Jackson RC; Jackman AL; Calvert AH
Biochem Pharmacol; 1983 Dec; 32(24):3783-90. PubMed ID: 6661252
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological activity of tricyclic antifolate compounds with fixed geometry.
Rosowsky A; Modest EJ
Ann N Y Acad Sci; 1971 Nov; 186():258-69. PubMed ID: 5002300
[No Abstract] [Full Text] [Related]
23. Raltitrexed, a novel folate-based thymidylate synthase inhibitor, for the treatment of acute leukemia: is this drug active against acute myelogenous leukemia?
Takemura Y; Kobayashi H; Miyachi H
Int J Hematol; 2000 Jul; 72(1):112-4. PubMed ID: 10979221
[No Abstract] [Full Text] [Related]
24. Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines.
Chen BK; Horváth C; Bertino JR
J Med Chem; 1979 May; 22(5):483-91. PubMed ID: 110930
[TBL] [Abstract][Full Text] [Related]
25. Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistance.
Calvert AH; Jones TR; Dady PJ; Grzelakowska-Sztabert B; Paine RM; Taylor GA; Harrap KR
Eur J Cancer (1965); 1980 May; 16(5):713-22. PubMed ID: 7389797
[No Abstract] [Full Text] [Related]
26. Estimation of the in vitro and in vivo inhibitory effects of antifolates upon thymidylate synthase (TS) in whole cells.
Taylor GA; Jackman AL; Balmanno K; Hughes LR; Calvert AH
Adv Exp Med Biol; 1989; 253B():383-8. PubMed ID: 2610126
[No Abstract] [Full Text] [Related]
27. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
28. New therapeutic strategies for patients with gastrointestinal malignancies using biochemical modulation of fluorouracil.
Allegra CJ
JAMA; 1995 Jan; 273(3):236-9. PubMed ID: 7807664
[No Abstract] [Full Text] [Related]
29. Substituted-2-desamino-2-methyl-quinazolinones. A series of novel antitumour agents.
Boyle FT; Matusiak ZS; Hughes LR; Slater AM; Stephens TC; Smith MN; Brown M; Kimbell R; Jackman AL
Adv Exp Med Biol; 1993; 338():585-8. PubMed ID: 8304185
[No Abstract] [Full Text] [Related]
30. ICI D1694, an inhibitor of thymidylate synthase for clinical study.
Jackman AL; Jodrell DI; Gibson W; Stephens TC
Adv Exp Med Biol; 1991; 309A():19-23. PubMed ID: 1789205
[TBL] [Abstract][Full Text] [Related]
31. Thymidylate synthetase as target enzyme for the inhibitory activity of 5-substituted 2'-deoxyuridines on mouse leukemia L1210 cell growth.
De Clercq E; Balzarini J; Torrence PF; Mertes MP; Schmidt CL; Shugar D; Barr PJ; Jones AS; Verhelst G; Walker RT
Mol Pharmacol; 1981 Mar; 19(2):321-30. PubMed ID: 7231392
[No Abstract] [Full Text] [Related]
32. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
[TBL] [Abstract][Full Text] [Related]
33. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
[TBL] [Abstract][Full Text] [Related]
34. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
35. Thymidylate synthase inhibitors in colorectal cancer.
Cassidy J
Semin Oncol; 2000 Oct; 27(5 Suppl 10):83-7. PubMed ID: 11049037
[No Abstract] [Full Text] [Related]
36. Quinazoline antifolates thymidylate synthase inhibitors: lipophilic analogues with modification to the C2-methyl substituent.
Hennequin LF; Boyle FT; Wardleworth JM; Marsham PR; Kimbell R; Jackman AL
J Med Chem; 1996 Feb; 39(3):695-704. PubMed ID: 8576912
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the biological effects of selected 5,8-dideazafolate analogues with their 2-desamino counterparts.
Hynes JB; Patil SA; Hagan RL; Cole A; Kohler W; Freisheim JH
J Med Chem; 1989 Apr; 32(4):852-6. PubMed ID: 2704031
[TBL] [Abstract][Full Text] [Related]
38. Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid.
Smith GK; Amyx H; Boytos CM; Duch DS; Ferone R; Wilson HR
Cancer Res; 1995 Dec; 55(24):6117-25. PubMed ID: 8521402
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).
Cantwell BM; Harris AL
Br J Cancer; 1988 Aug; 58(2):189-90. PubMed ID: 3166908
[No Abstract] [Full Text] [Related]
40. Folate-based inhibitors of thymidylate synthase: synthesis and antitumor activity of gamma-linked sterically hindered dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Bavetsias V; Jackman AL; Marriott JH; Kimbell R; Gibson W; Boyle FT; Bisset GM
J Med Chem; 1997 May; 40(10):1495-510. PubMed ID: 9154971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
